$HALB Halberd-Mississippi State University (MSU) T
Post# of 630
(Total Views: 183)
Posted On: 08/14/2023 9:15:33 AM
$HALB Halberd-Mississippi State University (MSU) Testing of TBI Nasal Spray Progresses
https://www.accesswire.com/773933/Halberd-Mis...Progresses
Scientific Paper Presented at Research Symposium
JACKSON CENTER, PA / ACCESSWIRE / August 14, 2023 / Halberd Corporation's (OTC PINK:HALB) Traumatic Brain Injury (TBI) mitigation research on Halberd's patent-pending nasal spray continues at Mississippi State University (MSU). MSU students, Jourdan, L.K., Broadaway, S. Cassen, et. al. authored and presented a paper on this project at the recent Mississippi State University Shackouls Honors College Summer Undergraduate Research Symposium, on August 2, titled "MODEL FOR THERAPEUTIC DEVELOPMENT IN TRAUMATIC BRAIN INJURY."
The research, headed by Dr. Russell Carr of the Mississippi State University College of Veterinary Medicine (MSU CVM), is designed to quantify and correlate bio-markers of TBI in animal models and to measure Halberd's nasal spray mitigation of the negative effects of TBI. The operative scientific assumption is that the maximum efficacy occurs when administered within hours of the traumatic injury event.
Halberd's nasal spray employs a proprietary blend of three active ingredients designed to timely address and block the excess production of certain identified inflammatory cytokines and neurotransmitters triggered by head trauma. Excess quantities of these elements are associated with irreversible brain injury.
Dr. Mitchell Felder, the principal inventor and Halberd's Chief Scientist, emphasizes the necessity of early administration of the nasal spray, perhaps within 10 minutes of head trauma for maximum efficacy. This mandates something simple and easy to administer, thus, a simple nasal spray applicator design.
According to the CDC, "In 2019, for example, CDC estimated that ‘the economic cost of [head trauma] injury was $4.2 trillion, including $327 billion in medical care, $69 billion in work loss, and $3.8 trillion in value of statistical life and quality of life losses"1. The potential market for a product that proactively treats and prevents TBI through the timely suppression of specific excess neurotransmitters and inflammatory cytokines associated with brain trauma is enormous. Currently, no other product on the market addresses this need, let alone in the requisite timely manner. If the MSU test results are positive, this will be a significant step towards realizing Halberd's first therapeutic product, with enormous economic and humanitarian potential, particularly for the military and those in contact sports.
https://www.accesswire.com/773933/Halberd-Mis...Progresses
Scientific Paper Presented at Research Symposium
JACKSON CENTER, PA / ACCESSWIRE / August 14, 2023 / Halberd Corporation's (OTC PINK:HALB) Traumatic Brain Injury (TBI) mitigation research on Halberd's patent-pending nasal spray continues at Mississippi State University (MSU). MSU students, Jourdan, L.K., Broadaway, S. Cassen, et. al. authored and presented a paper on this project at the recent Mississippi State University Shackouls Honors College Summer Undergraduate Research Symposium, on August 2, titled "MODEL FOR THERAPEUTIC DEVELOPMENT IN TRAUMATIC BRAIN INJURY."
The research, headed by Dr. Russell Carr of the Mississippi State University College of Veterinary Medicine (MSU CVM), is designed to quantify and correlate bio-markers of TBI in animal models and to measure Halberd's nasal spray mitigation of the negative effects of TBI. The operative scientific assumption is that the maximum efficacy occurs when administered within hours of the traumatic injury event.
Halberd's nasal spray employs a proprietary blend of three active ingredients designed to timely address and block the excess production of certain identified inflammatory cytokines and neurotransmitters triggered by head trauma. Excess quantities of these elements are associated with irreversible brain injury.
Dr. Mitchell Felder, the principal inventor and Halberd's Chief Scientist, emphasizes the necessity of early administration of the nasal spray, perhaps within 10 minutes of head trauma for maximum efficacy. This mandates something simple and easy to administer, thus, a simple nasal spray applicator design.
According to the CDC, "In 2019, for example, CDC estimated that ‘the economic cost of [head trauma] injury was $4.2 trillion, including $327 billion in medical care, $69 billion in work loss, and $3.8 trillion in value of statistical life and quality of life losses"1. The potential market for a product that proactively treats and prevents TBI through the timely suppression of specific excess neurotransmitters and inflammatory cytokines associated with brain trauma is enormous. Currently, no other product on the market addresses this need, let alone in the requisite timely manner. If the MSU test results are positive, this will be a significant step towards realizing Halberd's first therapeutic product, with enormous economic and humanitarian potential, particularly for the military and those in contact sports.
(0)
(0)Halberd Corporation (HALB) Stock Research Links
Scroll down for more posts ▼